ATURZURV Trademark

Trademark Overview

On Monday, July 8, 2024, a trademark application was filed for ATURZURV with the United States Patent and Trademark Office. The USPTO has given the ATURZURV trademark a serial number of 79402373. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, February 3, 2025. This trademark is owned by Boehringer Ingelheim International GmbH. The ATURZURV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; Pharmaceutical preparations for the treatment and prevention ...
aturzurv

General Information

Serial Number79402373
Word MarkATURZURV
Filing DateMonday, July 8, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, February 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; Pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; Pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseases.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 29, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBoehringer Ingelheim International GmbH
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDE

Trademark Events

Event DateEvent Description
Thursday, August 29, 2024LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, August 15, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, October 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 1, 2024APPLICATION FILING RECEIPT MAILED
Monday, February 3, 2025REFUSAL PROCESSED BY MPU
Tuesday, December 31, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, December 28, 2024ASSIGNED TO EXAMINER
Monday, December 30, 2024NON-FINAL ACTION WRITTEN

Related Keywords

aturzurv treatment pharmaceutical prevention preparations disorders diseases system nervous blood skin